Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of BI 3810477 in Healthy Males
NCT06631430Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Oct 2024
- Primary completion
- Jun 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of BI3810477 (11 arms), sponsored by Boehringer Ingelheim. Primary endpoint: Occurrence of any treatment-emergent adverse event assessed as drug-related by the investigator. Started Oct 2024; status: completed.
02
Drugs
BI3810477
Beyond the preview
Go deeper on NCT06631430.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06631430.